Yesterday, the FDA issued a warning stating that diabetes drugs containing Saxagliptin and Alogliptin may increase the risk of Heart Failure, especially in patients with heart or kidney disease.
As a result, the FDA is adding new warnings to the drug labels about the risk.
The FDA is recommending health care professionals consider discontinuing saxagliptin and alogliptin in patients who develop heart Failure. Saxagliptin and alogliptin are DPP-4 inhibitors that decreases blood sugar.
Saxagliptin and alogliptin are marketed under several trade names including:
- Onglyza (saxagliptin)
- Kombiglyze XR (saxagliptin and metformin extended release)
- Nesina (alogliptin)
- Kazano (alogliptin and metformin)
- Oseni (alogliptin and pioglitazone)
Signs and Symptoms of heart failure include:
- Unusual shortness of breath during daily activities
- Trouble breathing when lying down
- Tiredness, weakness, or fatigue
- Weight gain with swelling in the ankles, feet, legs, or stomach
If you are taking Onglyza or Kombiglyze XR and are experiencing any of the symptoms above, it’s urgent that you contact your health care professional.
This post first appeared on Meshbesher & Spence | Personal Injury, Medical Device Lawsuits, Car Accidents, please read the originial post: here
